He served as CEO at Holostem, Executive Director at the facility of Children Hospital Bambino Gesù in Rome, CEO of Xellbiogene, and Operations Director at MolMed.
Master’s Degree in Chemistry, University of Parma
25 years of management experience in the life science industry, specifically in clinical operations management, pharma business development and market access. Covering different role such as CEO, Executive Director and Chief Operating Officer for the management of Biotech Products & Advance Therapies Medicinal Products in the fields of Clinical and Operation development and Regulatory Affairs, Technology transfer, scale up & industrialization.
27th January 2023
An Opinion paper entitled “Plant-Derived Extracellular Vesicles as a Platform for Drug Delivery” was just published in Innovations in Tissue Engineering & Regenerative Medicine. The publication describes the advantages of plant-derived extracellular vesicles as carriers and their relevance for the future of drug delivery. The complete article at the link: https://crimsonpublishers.com/iterm/pdf/ITERM.000523.pdf
24th January 2023
Evobiotech received the recognition for the successful completion of the incubation program 2019-2022 of Incubatore d’Imprese 2i3T. Three years of growth and activities that brought the company to develop multiple therapeutic platforms using plant-derived extracellular vesicles.
BOARD AND TEAM
14th November 2022
Turin, November 14th 2022 EvoBiotech S.r.l. announces the appointment of Mr. Marco Dieci as member of the Board and Chief Operating Officer. EvoBiotech is a Biotech company developing a novel technology platform using plant-derived Extracellular Vesicles (EV) aimed at improving the healing efficacy of advanced dressings and medications used in wound care treatments and at […]